{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000153","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.735187+00:00","generated_at":"2026-06-11T12:41:33.017388+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing","bullets":["Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.","Net loss $24.9M vs $64.7M YoY, including $24.1M tax benefit from valuation allowance release on deferred tax assets.","R&D expenses $33.7M (Q2 2023) vs $53.7M (Q2 2022); G&A $13.3M vs $14.8M.","SerpinPC registrational PRESent-2 study first subject dosed July 2023; FDA Fast Track designation received May 2023.","LB206 (PD-L1xCD3 LockBody) nominated as second development candidate; ORX750 IND-enabling; preclinical data at World Sleep Congress Oct 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000153","json":"https://secwatch.observer/filing/0001847903-23-000153.json","markdown":"https://secwatch.observer/filing/0001847903-23-000153.md","text":"https://secwatch.observer/filing/0001847903-23-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/0001847903-23-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/cnta-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:41:33.017388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"beeb5af560f2d2884159a3a89a3b25d32b66017c","claim":"Centessa Pharmaceuticals plc reported for the second quarter ended June 30, 2023 results: net income $24.9 million.","evidence_excerpt":"Centessa Pharmaceuticals plc (the \"Company\") announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/0001847903-23-000153-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the second quarter ended June 30, 2023"},{"label":"Net income","value":"$24.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}